INBRX-101 is a recombinant human AAT-Fc fusion protein designed to replace the enzyme that is deficient in AATD and offer less frequent dosing than current therapies for the disease, based on ...

liver disease, or both, related to AATD. Per the company, approximately 200,000 individuals in the United States and EU have AATD due to the SERPINA1 Z mutation. Current treatments are limited to ...

We have identified and advanced a focused set of additional diseases and approaches that meet the same criteria. One such example is alpha-1 antitrypsin deficiency (AATD), which in many ways is ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD) lung disease In September, after initiating dosing in Cohort 2, the Company amended the protocol for its KB408 Phase 1 SERPENTINE-1 ...

Additionally, it formed a Clinical Advisory Board (CAB) of lung and liver disease experts to guide the therapy’s clinical development. "Korro secures approvals in Australia to commence AATD ...

Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from ...